TABLE 4.

Sterol composition of ketoconazole-treated AmB-sensitive and -resistant promastigotes^a

Sterolb	Trrc	% Total sterol
		AmB-sensitive cells		AmB-resistant cells
		Control	Exptl	Control	Exptl
Cholesterol (a)	1.00	13	18	27	14
14α-Methylcholesta-5, 7, 24-trien-3β-ol (j)	1.04	—d	—	—	4
Ergosta-5, 7, 22, 24 (28)-tetraen-3β-ol (i)	1.09	—	8	—	—
14α-Methylcholesta-8, 24-dien-3β-ol (k)	1.12	—	27	—	33
Cholesta-5, 7, 24-trien-3β-ol (c)	1.15	—	—	58	35
Ergosterol (b)	1.20	30	6	—	—
4, 4α-Dimethylcholesta-8, 24-dien-3β-ol (l)	1.24	—	—	—	3
4α, 14α-Dimethylcholesta-8, 24-dien-3β-ol (m)	1.26	—	—	—	5
14α-Methylergosta-8, 24 (28)-dien-3β-ol (n)	1.30	—	1	—	—
14α-Methylergosta-5, 7, 24 (28)-trien-3β-ol (f)	1.35	8	35	—	—
4α, 14α-Dimethylergosta-8, 24 (28)-dien-3β-ol (o)	1.38	—	4	—	—
24-Methylenedihydrolanosterol (h)	1.54	<1	<1	—	—

^aCells at logarithmic phase were treated for 24 h with 20 μM (AmB sensitive) or 0.2 μM (AmB resistant) ketoconazole. 

^bLetters in parentheses are for ease of cross-reference among Tables 3 to 5 and Fig. 4. 

^cTrr, retention time relative to cholesterol in GLC. 

^d—, not detected.